Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.
四 環 醫 藥 控 股 集 團 有 限 公 司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

RESIGNATION OF EXECUTIVE DIRECTOR, DEPUTY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF FINANCIAL OFFICER

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**", together with its subsidiaries, collectively the "**Group**") hereby announces that the following changes in office of the Company have taken place:

RESIGNATION OF EXECUTIVE DIRECTOR, DEPUTY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

Due to her focus on personal career development, Ms. Miao Guili ("**Ms. Miao**") has resigned as an executive director, the deputy chief executive officer and the chief financial officer of the Company, and has also ceased to serve as a co-chairman of the risk management committee of the Board, with effect from 26 August 2026.

Ms. Miao has confirmed that she has no disagreement with the Board, and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Company would like to express its gratitude to Ms. Miao for her contribution during her tenure of service as an executive director, the deputy chief executive officer and the chief financial officer of the Company.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Mr. Che Yuxuan has been appointed as a non-executive director of the Company and a member of the risk management committee of the Board, with effect from 26 August 2026. The biographical details of Mr. Che Yuxuan are set out below:

Mr. Che Yuxuan, aged 25, currently serves as the assistant to the chairperson of Xuanzhu Biopharmaceutical Co., Ltd. (stock code: 2575) (a listed company on the Stock Exchange). Mr. Che Yuxuan previously served as a data science researcher at Massachusetts General Hospital and engaged in the work of marketing and sales at Sanofi Pasteur. Since August 2024, Mr. Che Yuxuan has been serving as the assistant to the chairperson of Xuanzhu Biopharmaceutical Co., Ltd., and is mainly responsible for assisting the chairperson in coordinating strategic operations. He is also a director of certain companies of the Group. Mr. Che Yuxuan obtained a bachelor's degree in biology from the University of Washington.

Mr. Che Yuxuan is the son of Dr. Che Fengsheng, an executive director, the chairman of the Board and a controlling shareholder of the Company. Save as disclosed above, Mr. Che Yuxuan is not connected to and does not have any relationship with any other directors, senior management, substantial shareholders or controlling shareholders (each defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") respectively) of the Company.

As at the date of this announcement, save as disclosed above, Mr. Che Yuxuan (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold other positions with the Company and other members of the Group; and (iii) does not hold any directorship in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the past three years.

Mr. Che Yuxuan has entered into a letter of appointment with the Company for a term commencing on 26 August 2026 and ending on 25 August 2029. However, pursuant to the bye-laws of the Company, Mr. Che Yuxuan will hold office until the next annual general meeting of the Company and will be subject to retirement by rotation and re-election. Mr. Che Yuxuan will not receive any director's fee as a non-executive director, but is entitled to be reimbursed for all reasonable expenses incurred in the performance of his duties in connection with the business of the Company.

Save as disclosed above, there is no other information relating to Mr. Che Yuxuan that is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters relating to the appointment of Mr. Che Yuxuan that need to be brought to the attention of the shareholders of the Company.

The Company would like to extend its welcome to Mr. Che Yuxuan for joining the Board.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

Ms. Song Xiaomi ("**Ms. Song**") has been appointed as the chief financial officer of the Company with effect from 26 August 2026. The biographical details of Ms. Song are set out below:

Ms. Song Xiaomi, aged 59, is the director of the Planning and Finance Centre of the Group. Ms. Song has extensive experience in the PRC pharmaceutical industry/financial management, strategic operations and compliance system building. Prior to joining the Group, Ms. Song served as financial director and operations director of Beijing Konruns Pharmaceutical Co., Ltd. (stock code: 603590.SH), and successively served as operations and information management director, operations director, sales controlling department manager and finance manager of Bayer HealthCare Co., Ltd., as well as accounting supervisor at the China World Hotel of China World Trade Center Co., Ltd. Ms. Song obtained a master's degree in accounting from Deakin University (Australia). She is a Fellow Certified Practising Accountant (Australia) and an intermediate accountant of the PRC.

The Company would like to extend its welcome to Ms. Song for her new appointment.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 26 August 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Che Yuxuan; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.